Sichenzia Ross Ference LLP Represents Wize Pharma, Inc. in a $4.45 Million Private Placement
New York, NY – October 24, 2018 – Sichenzia Ross Ference LLP, announced today that it represented Wize Pharma, Inc. (OTCQB: “WIZP”), a clinical stage Israel based U.S. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common stock at $1.00 per share and 1,350 shares of newly created Series A preferred stock which is convertible at $1.00 per share.
The investors also received 100% 5 year Series A and 100% 6 month Series B warrants exercisable at $1.00 per share and $1.10 per share respectively. Wize received gross proceeds of $4.45 million.
The Sichenzia Ross Ference LLP team was led by Partner Gregory Sichenzia and Counsel Jeff Cahlon.
- Sichenzia Ross Ference LLP Represents Laidlaw & Company (UK) Ltd. in $5.75 Million Public Offering and Nasdaq Uplisting of Silo Pharma, Inc. - October 1, 2022
- Mid-Level Corporate Associate - September 29, 2022
- Junior Level Corporate Associate - September 29, 2022